Pneumoccoccal polysaccharide conjugate vaccine

Details Pneumoccoccal polysaccharide conjugate vaccine Pneumoccoccal polysaccharide conjugate vaccine

A - Human Necessities

61

K

A61K 47/48 (2006.01) A61K 39/09 (2006.01) A61K 39/095 (2006.01)

Patent

CA 2059692

A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.

Affiliated with

Also associated with

Rating

Pneumoccoccal polysaccharide conjugate vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pneumoccoccal polysaccharide conjugate vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pneumoccoccal polysaccharide conjugate vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1973215